Free cash flow remains consistently negative, with quarterly outflows often exceeding $8M, further obscured by stock-based compensation that reached $2.1M in 2026Q1.
| Cash from Operations | -17.06M | -18.71M | -35.5M | -51.24M | -46.52M | -32.24M | -14.96M | -26.27M |
| Operating CF Margin % | - | -1145.99% | -3452.92% | - | - | -1186.79% | -3238.1% | -2683.04% |
| Operating CF Growth % | 199.27% | 47.28% | 30.72% | -10.15% | -44.25% | -115.54% | 43.05% | - |
| Net Income | -29.44M | -29.67M | -56.58M | -33.97M | -63.34M | -8.33M | -16.7M | -26.59M |
| Depreciation & Amortization | 810K | 900K | 1.03M | 822K | 548K | 497K | 589K | 564K |
| Stock-Based Compensation | 6.67M | 11.8M | 16.03M | 19.01M | 15.78M | 22.59M | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.19M | -8.7M | 4.57M | -34.96M | -10K | -43.58M | 110K | -81K |
| Working Capital Changes | 5.97M | 6.96M | -544K | -2.14M | 509K | -3.43M | 1.04M | -163K |
| Change in Receivables | -1.01M | -1.61M | -428K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -662K | -1.05M | 711K | -595K | 163K | 543K | 933K | -271K |
| Cash from Investing | -27.71M | -7.03M | 19.81M | 29.86M | -72.44M | -506K | -1.2M | -1.53M |
| Capital Expenditures | -52K | -88K | -268K | -1.23M | -1.62M | -506K | -1.2M | -1.58M |
| CapEx % of Revenue | 1.64% | 5.39% | 26.07% | - | - | 18.62% | 259.74% | 161.49% |
| Acquisitions | 0 | 0 | 0 | 0 | -851K | 0 | 0 | 49K |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 244K | 278K | 1.25M | 0 | 851K | 0 | 0 | 0 |
| Cash from Financing | 44M | 40.3M | 13.59M | 233K | 29M | 77.15M | 72.68M | 852K |
| Debt Issued (Net) | -16.97M | -20.72M | -5M | 0 | 29.57M | -2.85M | 4.19M | 0 |
| Equity Issued (Net) | 58.23M | 61.08M | 18.63M | 395K | 317K | 79.97M | 71.27M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2.74M | -59K | -47K | -162K | -886K | 26K | -2.78M | 852K |
| Net Change in Cash | -767K | 14.56M | -2.1M | -21.14M | -89.95M | 44.4M | 56.52M | -26.95M |
| Free Cash Flow | -17.11M | -18.8M | -35.76M | -52.47M | -48.13M | -32.75M | -16.16M | -27.85M |
| FCF Margin % | -540.04% | -1151.38% | -3478.99% | - | - | -1205.41% | -3497.84% | -2844.54% |
| FCF Growth % | 50.46% | 47.43% | 31.83% | -9% | -46.97% | -102.67% | 41.97% | - |
| FCF per Share | -0.10 | -0.28 | -1.26 | -2.06 | -2.02 | -1.68 | -0.86 | -1.49 |
| FCF Conversion (FCF/Net Income) | 0.58x | 0.63x | 1.18x | 1.51x | 1.52x | 3.87x | 0.90x | 0.99x |
| Interest Paid | 0 | 0 | 0 | 4.18M | 730K | 285K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 35K | 48K | 73K | 0 | 0 |
Binary clinical liquidity risk
According to recent financial disclosures, RANI exhibits a persistent disconnect between net income and operating cash flow, with the OCF/NI ratio frequently exceeding 1.0, suggesting that non-cash expenses like stock-based compensation are significantly inflating the reported bottom line relative to actual cash consumption.
The reliance on stock-based compensation to manage cash burn appears to be a structural necessity rather than a performance-based incentive. Investors should monitor this divergence, as it indicates that the company's reported losses understate the true economic cost of funding its ongoing research and development activities.
As reported in quarterly filings, RANI's free cash flow remains consistently negative, with quarterly outflows often exceeding $8M, highlighting a trajectory that is entirely dependent on external capital infusions rather than internal cash generation from its nascent, milestone-driven revenue model.
The lack of a positive FCF trajectory suggests that the company is still in the high-intensity phase of platform validation. Without a shift toward recurring revenue or a significant reduction in clinical trial costs, the current cash burn rate appears unsustainable over the long term.
Based on the provided data, working capital changes are highly erratic, with swings ranging from a $6M inflow in 2025Q4 to a $3M outflow in 2023Q4, reflecting the unpredictable timing of milestone payments and the lack of a stable operational cycle.
These fluctuations suggest that the company's cash position is highly sensitive to the timing of partner-related cash receipts. This volatility complicates liquidity planning and may force management to maintain higher cash buffers than would otherwise be required in a more predictable business environment.
As indicated by the company's cash flow statements, stock-based compensation consistently offsets a meaningful portion of the net loss, effectively masking the true magnitude of the cash required to sustain the organization's current research and development operations.
While SBC is a standard tool for talent retention in biotech, its scale relative to the company's cash position warrants close scrutiny. Investors should interpret these figures as a form of hidden dilution that effectively subsidizes the company's inability to generate positive operating cash flow.
Quick answers to the most common questions about buying RANI stock.
Rani Therapeutics Holdings, Inc. (RANI) generated $-18.7M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Rani Therapeutics Holdings, Inc. (RANI) reported negative free cash flow of $18.8M in 2025, indicating capital requirements exceeded cash from operations.
Rani Therapeutics Holdings, Inc. (RANI) spent $0.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.